glp 1 drugs and depression GLP-1 Receptor Agonists in Mood Disorders: A Psychiatric Perspective GLP-1 medications used to treat

Outcomes included changes in left ventricular ejection fraction (LVEF), end-diastolic volume (LVEDV), end-systolic volume (LVESV), global longitudinal strain (GLS), left ventricular mass, left atrial volume (LAV), and NT-proBNP levels

GLP-1 is a hormone that the gut produces after eating to regulate blood sugar, slow digestion and manage hunger

and (iii) compound 2 and LY3502970 (a small molecule agonist), all in complex with heterotrimeric Gs

Jardiance (empagliflozin) 38% CV death reduction vs Mounjaro (tirzepatide) 21% weight loss (EMPA-REG vs SURPASS)

Amgens MariTide leads the GLP-1 obesity therapy market in 2025 with innovative design, Phase-3 trials, and strong potential for effective weight loss.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide and tirzepatide, have emerged as transformative agents for type 2 diabetes and obesity through their potent effects on weight reduction, insulin sensitivity, and cardiovascular outcomes